These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 16707525)
21. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Islam MS; Vernon SA; Negi A Eye (Lond); 2007 Mar; 21(3):321-3. PubMed ID: 16543927 [TBL] [Abstract][Full Text] [Related]
22. Intravitreal triamcinolone injection for diffuse diabetic macular edema with foveal cystoid changes. Barak A; Regenbogen M; Goldstein M; Loewenstein A Isr Med Assoc J; 2006 Feb; 8(2):83-7. PubMed ID: 16544727 [TBL] [Abstract][Full Text] [Related]
23. The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabeticfoveal oedema and cataract. Habib MS; Cannon PS; Steel DH BMC Ophthalmol; 2005 Jun; 5():15. PubMed ID: 15972106 [TBL] [Abstract][Full Text] [Related]
24. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Gillies MC; Islam FM; Zhu M; Larsson J; Wong TY Br J Ophthalmol; 2007 Oct; 91(10):1323-6. PubMed ID: 17405800 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Ciardella AP; Klancnik J; Schiff W; Barile G; Langton K; Chang S Br J Ophthalmol; 2004 Sep; 88(9):1131-6. PubMed ID: 15317702 [TBL] [Abstract][Full Text] [Related]
27. Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema. Karacorlu M; Ozdemir H; Senturk F; Karacorlu SA; Uysal O Acta Ophthalmol; 2010 Aug; 88(5):558-63. PubMed ID: 19432873 [TBL] [Abstract][Full Text] [Related]
28. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501 [TBL] [Abstract][Full Text] [Related]
29. Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. Margolis R; Singh RP; Bhatnagar P; Kaiser PK Acta Ophthalmol; 2008 Feb; 86(1):105-10. PubMed ID: 17608830 [TBL] [Abstract][Full Text] [Related]
30. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Patel PJ; Zaheer I; Karia N Eye (Lond); 2008 Jan; 22(1):60-4. PubMed ID: 16902493 [TBL] [Abstract][Full Text] [Related]
32. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract. Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251 [TBL] [Abstract][Full Text] [Related]
33. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Sørensen TL; Haamann P; Villumsen J; Larsen M Acta Ophthalmol Scand; 2005 Feb; 83(1):67-70. PubMed ID: 15715560 [TBL] [Abstract][Full Text] [Related]
34. Improved visual acuity and macular thickness 1 week after intravitreal triamcinolone for diabetic macular oedema. Islam MS; Negi A; Vernon SA Eye (Lond); 2005 Dec; 19(12):1325-7. PubMed ID: 15578081 [TBL] [Abstract][Full Text] [Related]